Recent studies have explored the potential of thyroid hormone receptor-beta agonists as therapeutic agents for MASLD, aiming to harness the metabolic regulatory functions of thyroid hormones to ameliorate liver steatosis and inflammation. The gene discussed is TG; the disease is fatty liver disease.